Work

Case Report: Influence of BRCA1 germline mutation on treatment-related morbidity of a non-seminomatous germ cell tumor patient

Year: 2025

Type: article

Abstract: germline variant following molecular testing due to a positive family history. While tumor analysis did not confirm loss of heterozygosity, evidence suggests that BRCA1 haploinsufficiency also increases genomic instability and cancer risk. After pre-phase treatment and the first cycle of chemotherapy, the patient developed prolonged pancytopenia leading to neutropenic sepsis. Subsequent cycles showed a shorter duration of pancytopenia, though it remained significant. A literature review indicates that BRCA1 deficiency may impair bone marrow recovery after chemotherapy, as observed in breast cancer patients, which we hypothesize also applies in this case. After first-line treatment, the patient had a partial response. In case of recurrence, the use of PARP inhibitors should be considered due to the BRCA1 deficiency.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2025.1579574